“Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s65. doi:10.25251/skin.5.supp.65.